Psoriatic Arthritis Clinical Trials in Philadelphia, Pennsylvania

4 studies are recruiting for psoriatic arthritis in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

    This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
    Locations
    52 in total
    Run by
    National Cancer Institute (NCI)

    See if you can join NCT03816345 on ClinicalTrials.gov

  2. Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

    Researchers are looking for new ways to treat Psoriatic Arthritis (PsA). This study will help find out if a study medicine called tulisokibart (MK-7240) can treat symptoms of active PsA. This study assesses the efficacy, safety, and tolerability of tulisokibart in adult participants with active PsA…

    Stage
    Phase 2
    Ages
    18 to 80
    Site
    Hospital of the University of Pennsylvania ( Site 5134), Philadelphia, Pennsylvania
    Locations
    50 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT07486960 on ClinicalTrials.gov

  3. A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

    A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)

    Stage
    Phase 4
    Ages
    18 and older
    Site
    University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    5 in total
    Run by
    CARE ARTHRITIS LTD.

    See if you can join NCT06454188 on ClinicalTrials.gov

  4. Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

    The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.

    Stage
    Phase 3
    Ages
    18 to 80
    Site
    Hospital at the University of Pennsylvania, Philadelphia, Pennsylvania
    Locations
    14 in total
    Run by
    University of Pennsylvania

    See if you can join NCT05669833 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.